FDA Updates eMDR Framework with ESG NextGen Submission Portal
The U.S. Food and Drug Administration (FDA) has published an update to its Electronic Medical Device Reporting (eMDR) system, confirming the transition to a new electronic submission environment. According to the latest update (April 10, 2026), the Electronic Submissions Gateway (ESG) NextGen Unified Submission Portal (USP) replaced the legacy WebTrader interface on April 14, 2025.
The ESG NextGen USP is described as a user-friendly, web-based platform that enables stakeholders to submit regulatory information electronically and track submission status through FDA Center receipt.
Overview of eMDR requirements
The FDA reiterates that electronic reporting remains mandatory for certain economic operators under 21 CFR Part 803.
Specifically:
Manufacturers (as defined in 21 CFR §803.3(l)) and importers (§803.3(j)) are required to submit individual adverse event reports in electronic format
These submissions must comply with §803.12(a) and §803.20
Exemptions from electronic reporting may be granted under §803.19, subject to FDA approval
The FDA also clarifies the obligations for other actors:
Distributors (§803.3(e)) are required to maintain records of incidents, but are not required to submit reports to the FDA
User facilities (§803.3(d)) may use electronic reporting, but are still permitted to submit written reports
System environment and supporting resources
The eMDR framework is supported by a range of FDA resources and system functionalities, including:
Information on how to enroll in the eMDR program
Documentation on the ESG NextGen system
Troubleshooting guidance and contact information
Frequently Asked Questions (FAQs)
Technical specifications such as Health Level Seven (HL7) Individual Case Safety Report (ICSR) formats
These elements support stakeholders in implementing and maintaining compliant electronic reporting processes.
Key update: transition to ESG NextGen
The main update highlighted by the FDA is the replacement of the WebTrader interface with the ESG NextGen USP. This marks a continuation of FDA efforts to modernise electronic submissions infrastructure.
The new portal provides:
A centralised submission interface
A web-based environment accessible to users
Functionality to monitor submission status after receipt by the FDA
No changes to the underlying regulatory reporting obligations are indicated in this update.
Conclusion
The FDA’s latest communication confirms that while the technical submission platform for eMDR has been updated, the core regulatory requirements under 21 CFR Part 803 remain unchanged.
Manufacturers and importers should ensure alignment with the ESG NextGen submission environment, as electronic reporting continues to be a mandatory requirement for adverse event reporting in the United States.
Read the full document below.
